TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04695223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)
Study: NCT05752149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRGD-ZW800-1
Description: Intravenous administration of study drug at lesat 2h prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRGD-ZW800-1
Description: Intravenous administration of study drug at lesat 2h prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRGD-ZW800-1
Description: Intravenous administration of study drug at lesat 2h prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRGD-ZW800-1
Description: Intravenous administration of study drug at lesat 2h prior to surgery
Study: NCT05117502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation
Description: intermittent Theta Burst Stimulation (iTBS) is a type of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered by the MagVenture MagPROX100 with MagOption Stimulator and MagPro Cool Coil B65 A/P. The MagPro Cool Coil B65 A/P can be switched from active to placebo.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intermittent Theta Burst Stimulation
Description: The placebo coil magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active iTBS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e. clicking) nearly identical to that of the active coil.
Study: NCT05282992

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native type II collagen
Description: 1 capsule/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule/day
Study: NCT05228600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-13027
Description: YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature.
Study: NCT06053333

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06009341

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given. In addition, the intervention group will be taught the training program and applications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given. In addition, the intervention group will be taught the training program and applications.
Study: NCT05186623

Intervention type: DRUG
Intervention: Vedolizumab, Ustekinumab, or Tofacitinib
Description: Drug administration and prospective follow-up for evaluating response
Study: NCT04873570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Moxifloxacin 400mg IR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: Moxifloxacin 400mg IR tablet
Study: NCT06256952

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: basic psychological assessment
Description: * Sociodemographics~* ASSIST~* Quantity Frequency: Alcohol, tobacco/e-cigarette, Cannabis \& other illegal drugs~* SCID: AUD criteria and tabak use disorder life time and last year \& acute depressive symptoms \& symptoms for Mania and psychotic disorder~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Allgemeine Depressionsskala (ADS)~* State-Trait-Anxiety Inventory (STAI-T)~* Alcohol Use Disorders Identification Test (AUDIT)~* Cannabis Use Disorder Identification Test (CUDIT)~* CAS -A (Alkohol)~* Fragebogen zur Sozialen Unterstützung (F-SozU K-14)~* Oslo-3-Items-Social-Support Scale~* Social Skills Rating System (SSRS)~* Trier Inventory for chronic stress (TICS)~* Rejection Sensitivity Questionnaires (RSQ-9)~* Need to belong scale (NTBS)~* Fragebogen zu Gedanken und Gefühlen (FGG-14)~* Internationale Trauma Questionnaire (ITQ)~* Zahlen-Symbol-Test (DST)~* Wortschatztest (verbal intelligence)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre and post cyberball task
Description: Positive and Negative Affect Schedule(PANAS)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre and post cyberball task
Description: Positive and Negative Affect Schedule(PANAS)
Study: NCT05983822

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technological Group
Description: Specific rehabilitation for the recovery of hand function using the end-effector robot
Study: NCT06256952

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre and post cyberball task
Description: Positive and Negative Affect Schedule(PANAS)
Study: NCT05983822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Group
Description: Specific rehabilitation for the recovery of hand function using the end-effector robot
Study: NCT05983822

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Conventional rehabilitation
Study: NCT05812001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergames-acceptance and commitment therapy (e-ACT)
Description: In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy (ACT)
Description: As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
Study: NCT06256952

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAS
Description: subjective arousal, subjective stress, valence, perceived ostracisms/loneliness

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAS
Description: subjective arousal, subjective stress, valence, perceived ostracisms/loneliness

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAS
Description: subjective arousal, subjective stress, valence, perceived ostracisms/loneliness

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAS
Description: subjective arousal, subjective stress, valence, perceived ostracisms/loneliness
Study: NCT05334862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 8 plate hemiepiphysiodesis
Description: surgical procedure by lateral incision in proximal tibia and distal femur and fixation by using 8 plate and screws.
Study: NCT06256952

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: after cyberball task
Description: * Need Threat Scale~* Manipulation check (VAS scale)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: after cyberball task
Description: * Need Threat Scale~* Manipulation check (VAS scale)
Study: NCT05316441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Positive Psychotherapy is a recently emerged therapy method that works on talents. In the study, success skill development psychoeducation based on positive psychotherapy will be applied.
Study: NCT06256952

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: after cyberball task
Description: * Need Threat Scale~* Manipulation check (VAS scale)
Study: NCT05996835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIN816 70 mg lyophilisate powder
Description: Immunotherapy Recombinant human CD39 enzyme
Study: NCT06256952

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: after cyberball task
Description: * Need Threat Scale~* Manipulation check (VAS scale)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social inclusion (Cyberball task)
Description: Social inclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social inclusion, ball tosses will be balanced between all three players.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social inclusion (Cyberball task)
Description: Social inclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social inclusion, ball tosses will be balanced between all three players.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social inclusion (Cyberball task)
Description: Social inclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social inclusion, ball tosses will be balanced between all three players.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social inclusion (Cyberball task)
Description: Social inclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social inclusion, ball tosses will be balanced between all three players.
Study: NCT06564298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg iv.gtt d1, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 10mg/kg iv.gtt d1, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX/XELOX
Description: SOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and S-1 40mg/m2 po bid d1-14, every 21 days XELOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and Capecitabine 1000mg/m2 po bid d1-14, every 21 days
Study: NCT06170476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542-60μg
Description: HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542-120μg
Description: HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542-180μg
Description: HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Study: NCT06405113

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
Description: Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
Description: Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab
Study: NCT06575010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20 mL Liposomal bupivacaine (Exparel) will be given in the shoulder block prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20 mL Liposomal bupivacaine (Exparel) will be given in the shoulder block prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.5% Inj
Description: 0.75% bupivacaine will be given in the shoulder block prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.5% Inj
Description: 0.75% bupivacaine will be given in the shoulder block prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg Dexamethasone will be given in the shoulder block prior to surgery
Study: NCT05996835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIN816 70 mg lyophilisate powder
Description: Immunotherapy Recombinant human CD39 enzyme

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIN816 70 mg lyophilisate powder
Description: Immunotherapy Recombinant human CD39 enzyme

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sterile saline solution
Study: NCT05592990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGI226
Description: NGI226 MP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MP
Study: NCT06291584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: In the exercise program, the first 5 minutes are for heating, and the last 5 minutes are for cooling. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. At the end of respiratory exercises, resistance exercise training will be started. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, hip extrudy, squat, and cat-decrease. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: In the exercise program, the first 5 minutes are for heating, and the last 5 minutes are for cooling. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. At the end of respiratory exercises, resistance exercise training will be started. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, hip extrudy, squat, and cat-decrease. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
Study: NCT06608030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: A single dose of 0.3mg / kg esketamine during induction of anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Receiving the same volume of normal saline during induction of anesthesia.
Study: NCT06606899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 MG
Description: Oral syrup melatonin 3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate
Description: Oral chloral hydrate (50 mg/kg, maximum 2 g)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalational Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalational Sevoflurane
Study: NCT06667960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK06
Description: Biparatopic anti-5T4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK06
Description: Biparatopic anti-5T4 antibody
Study: NCT06670950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYT-510
Description: Oral formulation A fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYT-510
Description: Oral formulation A fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYT-510
Description: Oral formulation B fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYT-510
Description: Oral formulation A fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral formulation
Study: NCT04643769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: Oral tablet - ORIN1001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: Oral tablet - ORIN1001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: Oral tablet - ORIN1001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet - placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet - placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet - placebo
Study: NCT06613243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine 0.2 mg/kg
Description: Esketamine 0.2 mg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg + dexmedetomidine 0.1 µg/kg
Description: A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.1 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg + dexmedetomidine 0.15 µg/kg
Description: A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.15 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg + dexmedetomidine 0.2 µg/kg
Description: A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.2 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
Study: NCT04923776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
Study: NCT06409741

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary sphincterotomy
Description: ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge.~The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.~For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary.~If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up.
Study: NCT06528990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: This includes the following key components: 1) assignment to a peer ostomate; 2) ostomy self-management skills building delivered through group telehealth sessions and led by trained ostomy nurses and peer ostomates; 3) intervention resource manual.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: standard of care, where patients and family caregivers are managed by the oncology care team. Care may include clinic visits for follow-up, cancer directed treatments, referrals to other medical specialties as needed, and institutional ostomy nurse support before and after surgery as needed.
Study: NCT06669559

Intervention type: OTHER
Group type: OTHER
Intervention: DROM-Test
Description: DROM test: a tool for assessing the ability to decide on returning home
Study: NCT06170814

Intervention type: OTHER
Intervention: Exercise
Description: Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. One group will be given external focus stimuli, the other group will be given internal focus stimuli.

Intervention type: OTHER
Intervention: Exercise
Description: Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. One group will be given external focus stimuli, the other group will be given internal focus stimuli.
Study: NCT05073133

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OAV101
Description: A single Gene Therapy IV infusion at 1.1e14 vector genome (vg)/kg over approximately 60 minutes